Skip to main content
Premium Trial:

Request an Annual Quote

Elixir Closes $19M Series B Financing Round

NEW YORK, Oct. 13 (GenomeWeb News) - Elixir Pharmaceuticals said that it has secured another $19 million in its Series B financing, bringing the total raised to $40.5 million.


Elixir said that the $19 million was contributed by undisclosed new investors.  In a previous round of Series B financing, MPM Capital, Oxford BioScience Partners, and Arch Venture Partners purchased $21.5 million in Elixir equity.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.